Akshaya Jayachandran
@nephromommy-akshu.bsky.social
MD Internal Medicine, PGI Chandigarh
DM Nephrology, CMC Vellore, India 🇮🇳
Passionate nephrologist ! 🩺 👩🏻⚕️
Perspicacious toddler mom ! 👩🏻🍼
DM Nephrology, CMC Vellore, India 🇮🇳
Passionate nephrologist ! 🩺 👩🏻⚕️
Perspicacious toddler mom ! 👩🏻🍼
Reposted by Akshaya Jayachandran
T3d
Benefits may vary, and results in the general population on CV risk and mortality are still
controversial.
Overall, the results of recent studies have been mixed results. Different study populations,
end points and dosing may account for the lack of clarity. #NephJC
December 3, 2025 at 2:43 AM
T3d
Benefits may vary, and results in the general population on CV risk and mortality are still
controversial.
Overall, the results of recent studies have been mixed results. Different study populations,
end points and dosing may account for the lack of clarity. #NephJC
Hey this is Akshaya, junior faculty from CMC Vellore, India.
Currently joining in from Taiwan 🇹🇼 - here for the APCN !
🐟
Honestly, most of my CKD patients are poor and I’ve been guilty of stopping some of their randomly prescribed fish oil because it costed them a whale!
#NephJC
Currently joining in from Taiwan 🇹🇼 - here for the APCN !
🐟
Honestly, most of my CKD patients are poor and I’ve been guilty of stopping some of their randomly prescribed fish oil because it costed them a whale!
#NephJC
December 3, 2025 at 2:06 AM
Hey this is Akshaya, junior faculty from CMC Vellore, India.
Currently joining in from Taiwan 🇹🇼 - here for the APCN !
🐟
Honestly, most of my CKD patients are poor and I’ve been guilty of stopping some of their randomly prescribed fish oil because it costed them a whale!
#NephJC
Currently joining in from Taiwan 🇹🇼 - here for the APCN !
🐟
Honestly, most of my CKD patients are poor and I’ve been guilty of stopping some of their randomly prescribed fish oil because it costed them a whale!
#NephJC
Reposted by Akshaya Jayachandran
Holy Mackerel! 🐟
🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴☠️ #NephJC
Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST
Check out the PISCES VA by @brianrifkin.bsky.social
www.nephjc.com/news/piscesva
🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴☠️ #NephJC
Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST
Check out the PISCES VA by @brianrifkin.bsky.social
www.nephjc.com/news/piscesva
PISCES: The Visual Abstract — NephJC
Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟 A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC! Check out the VA made by our master Brian...
www.nephjc.com
December 1, 2025 at 6:47 PM
Holy Mackerel! 🐟
🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴☠️ #NephJC
Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST
Check out the PISCES VA by @brianrifkin.bsky.social
www.nephjc.com/news/piscesva
🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴☠️ #NephJC
Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST
Check out the PISCES VA by @brianrifkin.bsky.social
www.nephjc.com/news/piscesva
A result this shiny usually means you check for scales! 🎣
Do read and enjoy our #NephJC summary/critical appraisal of the 🐟PISCES 🐟 Study (Fish Oil in Dialysis)
www.nephjc.com/news/pisces-...
@nephjc.bsky.social
Do read and enjoy our #NephJC summary/critical appraisal of the 🐟PISCES 🐟 Study (Fish Oil in Dialysis)
www.nephjc.com/news/pisces-...
@nephjc.bsky.social
December 1, 2025 at 7:25 PM
A result this shiny usually means you check for scales! 🎣
Do read and enjoy our #NephJC summary/critical appraisal of the 🐟PISCES 🐟 Study (Fish Oil in Dialysis)
www.nephjc.com/news/pisces-...
@nephjc.bsky.social
Do read and enjoy our #NephJC summary/critical appraisal of the 🐟PISCES 🐟 Study (Fish Oil in Dialysis)
www.nephjc.com/news/pisces-...
@nephjc.bsky.social
Reposted by Akshaya Jayachandran
⏰ 2 hours until chat tonight
#NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully?
👀See it for yourself
#NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully?
👀See it for yourself
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift
from supportive care to structured, evidence-based therapy
www.nephjc.com
November 19, 2025 at 12:00 AM
⏰ 2 hours until chat tonight
#NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully?
👀See it for yourself
#NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully?
👀See it for yourself
Reposted by Akshaya Jayachandran
TOM of this month goes to ACHIEVE trial (n=2,538), which showed that spironolactone 25 mg daily did not reduce CV events or mortality in dialysis patients, and increased risk of severe hyperkalemia #VA by
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.
November 10, 2025 at 1:22 PM
TOM of this month goes to ACHIEVE trial (n=2,538), which showed that spironolactone 25 mg daily did not reduce CV events or mortality in dialysis patients, and increased risk of severe hyperkalemia #VA by
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.
Reposted by Akshaya Jayachandran
Highlights from my talk yesterday on Alport syndrome spectrum of disorders. (since no one posted it, I'll have to do it myself)
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵
November 6, 2025 at 6:39 PM
Highlights from my talk yesterday on Alport syndrome spectrum of disorders. (since no one posted it, I'll have to do it myself)
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵
Reposted by Akshaya Jayachandran
Zigakibart was well tolerated and cut #proteinuria by 60% while stabilizing #kidney function in #IgAN patients over 100 weeks. #nephrology #nephsky #iganephropathy docwirenews.com/post/zigakib...
Zigakibart Demonstrates Safety and Efficacy in Phase 1/2 Trial | Docwire News
Zigakibart showed good tolerability, reduced proteinuria by 60%, and stabilized kidney function in patients with IgA nephropathy (IgAN) over 100 weeks of treatment.
docwirenews.com
October 30, 2025 at 6:03 PM
Zigakibart was well tolerated and cut #proteinuria by 60% while stabilizing #kidney function in #IgAN patients over 100 weeks. #nephrology #nephsky #iganephropathy docwirenews.com/post/zigakib...
Reposted by Akshaya Jayachandran
The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
www.nephjc.com
October 28, 2025 at 2:06 AM
The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
As nephrologists, we tend to focus on pathways, labs, and outcome curves. For years, IgAN meant familiar drugs and modest gains. Reading new guidelines through a patient’s story is a reminder of why it matters #nephjc
Perspective by @jonathanpollack.bsky.social
www.nephjc.com/news/2025/10...
Perspective by @jonathanpollack.bsky.social
www.nephjc.com/news/2025/10...
KDIGO IgA Guidelines: A Patient Voice — NephJC
We have a patient perspective on the new IgA Guidelines and what it means to live with IgA in these times.
www.nephjc.com
October 28, 2025 at 3:20 AM
Reposted by Akshaya Jayachandran
⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
KDIGO 2025 IgA guidelines - Visual Abstract — NephJC
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera
www.nephjc.com
October 27, 2025 at 5:27 PM
⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
Hey this is Akshaya, nephrologist from India! We’ve traditionally been restricting protein to our CKD patients until they go on to require dialysis ! A lot of our practices are changing nowadays though.
Would love to get some good-y food-y insights from this chat ! #NephJC
Would love to get some good-y food-y insights from this chat ! #NephJC
October 15, 2025 at 1:06 AM
Hey this is Akshaya, nephrologist from India! We’ve traditionally been restricting protein to our CKD patients until they go on to require dialysis ! A lot of our practices are changing nowadays though.
Would love to get some good-y food-y insights from this chat ! #NephJC
Would love to get some good-y food-y insights from this chat ! #NephJC
Reposted by Akshaya Jayachandran
Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR?
www.nephjc.com/news/2025/10...
www.nephjc.com/news/2025/10...
Protein supplementation in CKD: The Visual Abstract — NephJC
We like protein, or do we? Low protein, high protein, supplements…what’s a nephrologist to do?
www.nephjc.com
October 13, 2025 at 1:14 PM
Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR?
www.nephjc.com/news/2025/10...
www.nephjc.com/news/2025/10...
Reposted by Akshaya Jayachandran
Up next!
CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍
On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC
pubmed.ncbi.nlm.nih.gov/40876553/
#Skytorial by @nephromommy-akshu.bsky.social
Akshaya's signing off 👋
CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍
On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC
pubmed.ncbi.nlm.nih.gov/40876553/
#Skytorial by @nephromommy-akshu.bsky.social
Akshaya's signing off 👋
October 6, 2025 at 8:29 PM
Up next!
CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍
On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC
pubmed.ncbi.nlm.nih.gov/40876553/
#Skytorial by @nephromommy-akshu.bsky.social
Akshaya's signing off 👋
CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍
On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC
pubmed.ncbi.nlm.nih.gov/40876553/
#Skytorial by @nephromommy-akshu.bsky.social
Akshaya's signing off 👋
Reposted by Akshaya Jayachandran
10/10
Final #NephJC thoughts 🤔💭
While the study was a success, it is still a harsh reality that there exist many barriers to even getting a transplant. Much work is needed to safely simplify the procedure and make being IS - free a reliable reality for all kidney transplant patients!
#NephJC
Final #NephJC thoughts 🤔💭
While the study was a success, it is still a harsh reality that there exist many barriers to even getting a transplant. Much work is needed to safely simplify the procedure and make being IS - free a reliable reality for all kidney transplant patients!
#NephJC
October 6, 2025 at 8:29 PM
Reposted by Akshaya Jayachandran
9/10
I want more info: 👓📖
Please go through the insightful summary by Akshaya Jayachandran @nephromommy-akshu.bsky.social and Natalia Nombera @roxnonna23.bsky.social 🔖📖
🎨Beautiful visual abstract by Bogdan @thekidneywhisperer.bsky.social
#NephJC
www.nephjc.com/news/chimera...
I want more info: 👓📖
Please go through the insightful summary by Akshaya Jayachandran @nephromommy-akshu.bsky.social and Natalia Nombera @roxnonna23.bsky.social 🔖📖
🎨Beautiful visual abstract by Bogdan @thekidneywhisperer.bsky.social
#NephJC
www.nephjc.com/news/chimera...
October 6, 2025 at 8:29 PM
9/10
I want more info: 👓📖
Please go through the insightful summary by Akshaya Jayachandran @nephromommy-akshu.bsky.social and Natalia Nombera @roxnonna23.bsky.social 🔖📖
🎨Beautiful visual abstract by Bogdan @thekidneywhisperer.bsky.social
#NephJC
www.nephjc.com/news/chimera...
I want more info: 👓📖
Please go through the insightful summary by Akshaya Jayachandran @nephromommy-akshu.bsky.social and Natalia Nombera @roxnonna23.bsky.social 🔖📖
🎨Beautiful visual abstract by Bogdan @thekidneywhisperer.bsky.social
#NephJC
www.nephjc.com/news/chimera...
Reposted by Akshaya Jayachandran
8/10
#NephJC Quote of the fortnight from @brianrifkin.bsky.social 💬
Immune tolerance is nice, but unpredictable and requires constant vigilance to prevent rejection.
Would modifying graft kidneys to make them less antigenic be a better bet?
#NdphJC
#NephJC Quote of the fortnight from @brianrifkin.bsky.social 💬
Immune tolerance is nice, but unpredictable and requires constant vigilance to prevent rejection.
Would modifying graft kidneys to make them less antigenic be a better bet?
#NdphJC
October 6, 2025 at 8:29 PM
8/10
#NephJC Quote of the fortnight from @brianrifkin.bsky.social 💬
Immune tolerance is nice, but unpredictable and requires constant vigilance to prevent rejection.
Would modifying graft kidneys to make them less antigenic be a better bet?
#NdphJC
#NephJC Quote of the fortnight from @brianrifkin.bsky.social 💬
Immune tolerance is nice, but unpredictable and requires constant vigilance to prevent rejection.
Would modifying graft kidneys to make them less antigenic be a better bet?
#NdphJC
Reposted by Akshaya Jayachandran
7/10
Chat consensus? 🎬
Although the study shows that the MDR-101 regimen induces chimerism and functional immune tolerance in HLA-matched living donor KTRs leading to complete IS elimination, it is far from being widely applicable. It’s too costly and works only in highly HLA matched KTRs.
#NephJC
Chat consensus? 🎬
Although the study shows that the MDR-101 regimen induces chimerism and functional immune tolerance in HLA-matched living donor KTRs leading to complete IS elimination, it is far from being widely applicable. It’s too costly and works only in highly HLA matched KTRs.
#NephJC
October 6, 2025 at 8:29 PM
7/10
Chat consensus? 🎬
Although the study shows that the MDR-101 regimen induces chimerism and functional immune tolerance in HLA-matched living donor KTRs leading to complete IS elimination, it is far from being widely applicable. It’s too costly and works only in highly HLA matched KTRs.
#NephJC
Chat consensus? 🎬
Although the study shows that the MDR-101 regimen induces chimerism and functional immune tolerance in HLA-matched living donor KTRs leading to complete IS elimination, it is far from being widely applicable. It’s too costly and works only in highly HLA matched KTRs.
#NephJC
Reposted by Akshaya Jayachandran
6/10
Give me something clever to say 🤓
Here’s what caught my attention!
@kidneyboy.bsky.social comparing life on dialysis vs pig transplant 🐖+ IS vs Live donor transplant 🫘and IS free! Definitely stuff worthy of a sci-fi movie! 👽
Give me something clever to say 🤓
Here’s what caught my attention!
@kidneyboy.bsky.social comparing life on dialysis vs pig transplant 🐖+ IS vs Live donor transplant 🫘and IS free! Definitely stuff worthy of a sci-fi movie! 👽
October 6, 2025 at 8:29 PM
6/10
Give me something clever to say 🤓
Here’s what caught my attention!
@kidneyboy.bsky.social comparing life on dialysis vs pig transplant 🐖+ IS vs Live donor transplant 🫘and IS free! Definitely stuff worthy of a sci-fi movie! 👽
Give me something clever to say 🤓
Here’s what caught my attention!
@kidneyboy.bsky.social comparing life on dialysis vs pig transplant 🐖+ IS vs Live donor transplant 🫘and IS free! Definitely stuff worthy of a sci-fi movie! 👽
Reposted by Akshaya Jayachandran
5/10
A figure paints 🖼️ 1000 words!
KDQOL-SF36 data showed huge improvement in Burden of Kidney Disease and Mental Health Composite Scores at two and three years when patients were off IS. This demonstrates that even low-dose IS negatively impacts patient quality of life. 🙆💊
#NephJC
A figure paints 🖼️ 1000 words!
KDQOL-SF36 data showed huge improvement in Burden of Kidney Disease and Mental Health Composite Scores at two and three years when patients were off IS. This demonstrates that even low-dose IS negatively impacts patient quality of life. 🙆💊
#NephJC
October 6, 2025 at 8:29 PM
5/10
A figure paints 🖼️ 1000 words!
KDQOL-SF36 data showed huge improvement in Burden of Kidney Disease and Mental Health Composite Scores at two and three years when patients were off IS. This demonstrates that even low-dose IS negatively impacts patient quality of life. 🙆💊
#NephJC
A figure paints 🖼️ 1000 words!
KDQOL-SF36 data showed huge improvement in Burden of Kidney Disease and Mental Health Composite Scores at two and three years when patients were off IS. This demonstrates that even low-dose IS negatively impacts patient quality of life. 🙆💊
#NephJC
Reposted by Akshaya Jayachandran
4/10
One post results 📊
75% (15/20) of KTRs achieved functional immune tolerance (IS-free for two years) using the mixed chimerism strategy with MDR-101💉
The study showed 100% patient/graft survival and zero GVHD cases over three years, with improved quality of life. 4/20 KTRs resumed IS. #NephJC
One post results 📊
75% (15/20) of KTRs achieved functional immune tolerance (IS-free for two years) using the mixed chimerism strategy with MDR-101💉
The study showed 100% patient/graft survival and zero GVHD cases over three years, with improved quality of life. 4/20 KTRs resumed IS. #NephJC
October 6, 2025 at 8:29 PM
4/10
One post results 📊
75% (15/20) of KTRs achieved functional immune tolerance (IS-free for two years) using the mixed chimerism strategy with MDR-101💉
The study showed 100% patient/graft survival and zero GVHD cases over three years, with improved quality of life. 4/20 KTRs resumed IS. #NephJC
One post results 📊
75% (15/20) of KTRs achieved functional immune tolerance (IS-free for two years) using the mixed chimerism strategy with MDR-101💉
The study showed 100% patient/graft survival and zero GVHD cases over three years, with improved quality of life. 4/20 KTRs resumed IS. #NephJC
Reposted by Akshaya Jayachandran
3/10
One Post Methods 👩🏫
Phase 3, prospective, open-label, randomized, multicenter trial - USA/Canada. Included kidney transplant recipients (KTR) from a 2-haplotype HLA-matched, living donors.
Primary outcome - functional immune tolerance - staying off all IS for at least 24 months. 💊
#NephJC
One Post Methods 👩🏫
Phase 3, prospective, open-label, randomized, multicenter trial - USA/Canada. Included kidney transplant recipients (KTR) from a 2-haplotype HLA-matched, living donors.
Primary outcome - functional immune tolerance - staying off all IS for at least 24 months. 💊
#NephJC
October 6, 2025 at 8:29 PM
3/10
One Post Methods 👩🏫
Phase 3, prospective, open-label, randomized, multicenter trial - USA/Canada. Included kidney transplant recipients (KTR) from a 2-haplotype HLA-matched, living donors.
Primary outcome - functional immune tolerance - staying off all IS for at least 24 months. 💊
#NephJC
One Post Methods 👩🏫
Phase 3, prospective, open-label, randomized, multicenter trial - USA/Canada. Included kidney transplant recipients (KTR) from a 2-haplotype HLA-matched, living donors.
Primary outcome - functional immune tolerance - staying off all IS for at least 24 months. 💊
#NephJC
Reposted by Akshaya Jayachandran
2/10
What’d I miss?
Transplant immunosuppression (IS) causes significant drug toxicities, infection, cancer risks & huge costs 💸. “Functional tolerance” is a state in which the recipient’s immune system accepts the graft without additional IS. It has remained the "Holy grail" of transplant! #NephJC
What’d I miss?
Transplant immunosuppression (IS) causes significant drug toxicities, infection, cancer risks & huge costs 💸. “Functional tolerance” is a state in which the recipient’s immune system accepts the graft without additional IS. It has remained the "Holy grail" of transplant! #NephJC
October 6, 2025 at 8:29 PM
2/10
What’d I miss?
Transplant immunosuppression (IS) causes significant drug toxicities, infection, cancer risks & huge costs 💸. “Functional tolerance” is a state in which the recipient’s immune system accepts the graft without additional IS. It has remained the "Holy grail" of transplant! #NephJC
What’d I miss?
Transplant immunosuppression (IS) causes significant drug toxicities, infection, cancer risks & huge costs 💸. “Functional tolerance” is a state in which the recipient’s immune system accepts the graft without additional IS. It has remained the "Holy grail" of transplant! #NephJC
Reposted by Akshaya Jayachandran
1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed tolerance induction in HLA matched 🫘 transplants with donor Hematopoietic stem cells (MDR-101).
Missed the Chimeri-chat? No worries - We’re quite “tolerant” to those who missed their IS(Informative Session)!
pubmed.ncbi.nlm.nih.gov/39922283/
Welcome to #TenPostNephJC
Last #NephJC we discussed tolerance induction in HLA matched 🫘 transplants with donor Hematopoietic stem cells (MDR-101).
Missed the Chimeri-chat? No worries - We’re quite “tolerant” to those who missed their IS(Informative Session)!
pubmed.ncbi.nlm.nih.gov/39922283/
October 6, 2025 at 8:29 PM
1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed tolerance induction in HLA matched 🫘 transplants with donor Hematopoietic stem cells (MDR-101).
Missed the Chimeri-chat? No worries - We’re quite “tolerant” to those who missed their IS(Informative Session)!
pubmed.ncbi.nlm.nih.gov/39922283/
Welcome to #TenPostNephJC
Last #NephJC we discussed tolerance induction in HLA matched 🫘 transplants with donor Hematopoietic stem cells (MDR-101).
Missed the Chimeri-chat? No worries - We’re quite “tolerant” to those who missed their IS(Informative Session)!
pubmed.ncbi.nlm.nih.gov/39922283/
Reposted by Akshaya Jayachandran
What great cha
Excellent article
Fantastic write up for the summary
Great chat with good turn out
This is a good week for #NephJC
Thanks everyone
Excellent article
Fantastic write up for the summary
Great chat with good turn out
This is a good week for #NephJC
Thanks everyone
October 1, 2025 at 2:06 AM
What great cha
Excellent article
Fantastic write up for the summary
Great chat with good turn out
This is a good week for #NephJC
Thanks everyone
Excellent article
Fantastic write up for the summary
Great chat with good turn out
This is a good week for #NephJC
Thanks everyone